A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients

Trial Profile

A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 May 2013

At a glance

  • Drugs Metformin (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 14 May 2013 Additional lead trial center identified as reported by ClinicalTrials.gov.
    • 19 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top